Ocular Hypertension Market Expected to Rise | Companies – Nicox, Qlaris Bio, TheratOcular Biotek, Ocular Therapeutix, Whitecap Biosciences, JeniVision, AbbVie, Santen, Expected to Boost Market

Ocular Hypertension Market
DelveInsight’s “Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ocular Hypertension market growth is driven by factors like increase in the prevalence of Ocular Hypertension, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Ocular Hypertension market report also offers comprehensive insights into the Ocular Hypertension market size, share, Ocular Hypertension epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Ocular Hypertension market size growth forward. 

Some of the key highlights from the Ocular Hypertension Market Insights Report:

Several key pharmaceutical companies, including Nicox, Qlaris Bio, TheratOcular Biotek, Ocular Therapeutix, Whitecap Biosciences, JeniVision, AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others, are developing novel products to improve the Ocular Hypertension treatment outlook. 
The total Ocular Hypertension market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Ocular Hypertension market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Ocular Hypertension Market Landscape

Ocular Hypertension Overview 

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged – and intraocular pressure might be normal or high – which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.

In the United States, the prevalence of ocular hypertension in non-Hispanic Whites who are 40 years of age and older is 4.5 percent, and increases up to 7.7 percent in 75 to 79 year olds. In Latinos, the prevalence across ages is quite similar. Because ocular hypertension occurs typically without symptoms, a majority of people with ocular hypertension remains undiagnosed. In the Los Angeles Latino Eye Study, 75 percent of Latinos with eye pressures greater than 21 mmHg were previously undiagnosed. Ocular hypertension is caused by a malfunction of the drainage system for the aqueous humour, the fluid whose function is to bathe and nourish the ocular structures. When it does not flow correctly for different reasons, the balance between the fluid produced inside the eye and the fluid released from it is broken, leading to an increase in intraocular pressure (normally gradual, although it may also be sudden).

For diagnosis of OHT, patients should be offered the following tests: central visual field assessment using standard automated perimetry; optic nerve assessment and fundus examination using stereoscopic slit lamp biomicroscopy (with pupil dilatation if necessary); optical coherence tomography (OCT) or optic nerve head imaging; intraocular pressure (IOP) measurement using Goldmann-type applanation tonometry; peripheral anterior chamber configuration and depth assessments using gonioscopy.

The most usual type of treatment to be prescribed is eye drops that control the pressure within the eye, (these are the same drugs that are used to control glaucoma) by either reducing the amount of aqueous humour being produced by the eye (the ciliary body) or increasing the rate of drainage. There have been major advances in these forms of treatments in recent years and eye drops are now more effective and have fewer side effects than those that were previously available. Medications to lower pressure in your eyes include- Prostaglandins, Beta-blockers, Alpha-adrenergic agonists, Carbonic anhydrase inhibitors, Rho kinase inhibitor, and Miotic or cholinergic agents, among others. In some cases (or if eye drops are ineffective in reducing IOP), other glaucoma treatment measures, including glaucoma/laser surgery could be recommended, to treat high eye pressure. The bottom line is that a patient with ocular hypertension should have long-term follow-up with the physician to monitor the potential development of glaucoma or to gauge the effectiveness of treatments that are implemented.

Do you know the treatment paradigms for different countries? Download our Ocular Hypertension Market Sample Report

Ocular Hypertension Epidemiology Segmentation 

DelveInsight’s Ocular Hypertension market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Ocular Hypertension historical patient pools and forecasted Ocular Hypertension patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Ocular Hypertension Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Ocular Hypertension Prevalence 
Age-Specific Ocular Hypertension Prevalence 
Gender-Specific Ocular Hypertension Prevalence 
Diagnosed and Treatable Cases of Ocular Hypertension

Visit for more @ Ocular Hypertension Epidemiological Insights

Ocular Hypertension Treatment Market 

The Ocular Hypertension market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Ocular Hypertension market trends by analyzing the impact of current Ocular Hypertension therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Ocular Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Ocular Hypertension market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Ocular Hypertension market in 7MM is expected to witness a major change in the study period 2019-2032.

Ocular Hypertension Key Companies

Qlaris Bio
TheratOcular Biotek
Ocular Therapeutix
Whitecap Biosciences
VivaVision Biotech
ONL Therapeutics
Skye Bioscience
MediPrint Ophthalmics
Sun Pharma Advanced Research Company
Ripple Therapeutics
Peregrine Ophthalmic
Laboratorios Sophia
Whitecap Biosciences
pH Pharma
Chong Kun Dang
Laboratoires Thea

For more information, visit Ocular Hypertension Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Ocular Hypertension Market Report:

11 Years Forecast
7MM Coverage 
Descriptive overview of Ocular Hypertension, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Ocular Hypertension epidemiology in the 7MM
Ocular Hypertension marketed and emerging therapies 
Ocular Hypertension companies
Ocular Hypertension market drivers and barriers 

Key Questions Answered in the Ocular Hypertension Market Report 2032:

What was the Ocular Hypertension market share distribution in 2019, and how would it appear in 2032?
What is the total Ocular Hypertension market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Ocular Hypertension market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Ocular Hypertension market projected to expand at 7MM?

Table of Contents:

1 Ocular Hypertension Market Key Comprehensive Insights 

2 Ocular Hypertension Market Report Introduction

3 Competitive Intelligence Analysis for Ocular Hypertension

4 Ocular Hypertension Market Analysis Overview at a Glance

5 Executive Summary of Ocular Hypertension

6 Ocular Hypertension Epidemiology and Market Methodology

7 Ocular Hypertension Epidemiology and Patient Population

8 Ocular Hypertension Patient Journey

9 Ocular Hypertension Treatment Algorithm, Ocular Hypertension Current Treatment, and Medical Practices

10 Key Endpoints in Ocular Hypertension Clinical Trials

11 Ocular Hypertension Marketed Therapies 

12 Ocular Hypertension Emerging Therapies

13 Ocular Hypertension: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Ocular Hypertension

16 Ocular Hypertension Market Key Opinion Leaders Reviews

18 Ocular Hypertension Market Drivers

19 Ocular Hypertension Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Ocular Hypertension Epidemiology 2032

DelveInsight’s “Ocular Hypertension – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Ocular Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Ocular Hypertension Pipeline 2023

“Ocular Hypertension Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ocular Hypertension market. A detailed picture of the Ocular Hypertension pipeline landscape is provided, which includes the disease overview and Ocular Hypertension treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: